Abstract:In this study, including 54 PCNSL patients with 175 HD‐MTX‐based chemotherapy courses, the rate of AKI and myelosuppression increased significantly in patients treated with HD‐MTX co‐administered with VDS. We also found a significant correlation between MTX pharmacokinetics, eGFR before MTX infusion, and toxicity. What is Known and Objective Methotrexate (MTX) is an antimetabolic antitumor drug with high individual differences and may lead to severe toxicities in a considerable number of patients. This study aimed to explore the factors influencing major adverse events in patients with primary central nervous system lymphoma treated with high‐dose MTX (HD‐MTX), which could be useful in clinical practice. Methods Fifty‐four patients who received 175 courses of MTX at 3–8 g/m2 between January 2015 and December 2016 were enrolled in this study. We assessed the association between clinical characteristics, MTX pharmacokinetics, MTX delayed elimination, and adverse events, including hepatotoxicity, acute kidney injury (AKI), and myelosuppression. Results and Discussion A total of 124 adverse events occurred after MTX infusion. Using independent sample t‐tests, we found that patients with myelosuppression had higher MTX area under the concentration‐time curve up to 48 h after infusion (AUC0‐48h) (p = 0.001) and MTX peak concentration (Cmax) (p = 0.002). MTX concentrations at 48 and 72 h were higher in patients with AKI than in those without (p = 0.034 and p = 0.041, respectively). Using chi‐square tests, we found that AKI was correlated with MTX elimination at either 48 h or 72 h (22.1% vs. 8.2%, p = 0.010). By multivariate logistic regression model, our results showed that baseline level of ALT and WBC had a significant effect on hepatotoxicity (OR = 1.079, 95% CI 1.044–1.116, p = 6.9 × 10−6; OR = 0.808, 95% CI 0.711–0.917, p = 0.001, respectively). Patient's age, eGFR before MTX infusion, and co‐administration of vindesine had a significant effect on AKI (OR = 0.960, 95% CI 0.935–0.986, p = 0.003; OR = 1.009, 95% CI 1.001–1.017, p = 0.034; OR = 5.463, 95% CI 1.793–16.646, p = 0.003, respectively). LDH and Co‐administration of vindesine had a significant effect on myelosuppression (OR = 0.985, 95% CI 0.972–0.998, p = 0.025; OR = 3.070, 95% CI 1.032–9.133, p = 0.044). What is New and Conclusion Our study demonstrated that co‐administration of VDS, eGFR before MTX infusion, and the baseline index of laboratory examinations including ALT, WBC, LDH may be useful biomarkers for predicting MTX‐induced toxicities.

Population Pharmacokinetic and Toxicity Analysis of High-Dose Methotrexate in Patients with Central Nervous System Lymphoma

Risk factors for high‐dose methotrexate associated toxicities in patients with primary central nervous system lymphoma

High-dose Methotrexate Plus Temozolomide As a Salvage Treatment in Metastatic Central Nervous System Lymphoma: Two Cases Report and Review of Literature.

High-dose methotrexate dosing strategy in primary central nervous system lymphoma

Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma

Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis

The Effect of the Plasma Methotrexate Concentration During High-Dose Methotrexate Therapy in Childhood Acute Lymphoblastic Leukemia.

Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia

Risk factors associated with high-dose methotrexate induced toxicities

[Adverse Effects of High-Dose Methotrexate Therapy].

Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing

Improvement of outcomes of an escalated high‐dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study

Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese

A study on pharmacokinetics of high dose methotrexate (HD-MTX) in adults with acute lymphoblastic leukemia

Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma

[Population Pharmacokinetics of High-Dose Methotrexate Administered in 329 Children with Acute Lymphoblastic Leukemia].

Potential neurotoxicity associated with methotrexate

First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study